Elicio Therapeutics Reports Q2 2026 Results and Corporate Update

What Happened
Elicio Therapeutics, Inc. (ELTX) announced its quarterly financial results for the quarter ended June 30, 2026 and provided corporate updates in a press release dated August 13, 2026. The company furnished the full press release as Exhibit 99.1 to its Form 8-K. The filing was signed by Robert Connelly, President and Chief Executive Officer.

Key Details

• Form 8-K filed August 13, 2026 under Item 2.02 (Results of Operations and Financial Condition).
• The press release with the quarterly results and corporate updates is furnished as Exhibit 99.1.
• The company states the information in this 8-K (including Exhibit 99.1) is furnished, not “filed,” for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings except as expressly stated.

Why It Matters
This 8-K notifies investors that Elicio has released its latest quarterly earnings and company updates; investors should review the Exhibit 99.1 press release for specific financial figures (revenue, net income/loss, cash position, guidance) and operational details. Because the release is furnished rather than filed for Section 18 purposes, investors should also watch for subsequent SEC filings (e.g., Form 10-Q) for the company’s formally filed financial statements and disclosures.